Board & Non-Executive Director Search in Boston, Massachusetts
We run board and non-executive director searches for Boston issuers, hospital systems and sponsor-backed platforms, where a Massachusetts seat is a three-year class term shareholders cannot unwind without cause.
›A board search Boston file stalls on the three-year class term, not on the shortlist.
Sartori & Partners is highly technical in Board & Non-Executive Director Search work in Boston: 8 closed searches over three years, 94% completion, a median inside a 4 to 7 month band. Across 250 structured interviews with Boston partners, counsel and sitting directors, the blocker is rarely supply. Under Massachusetts corporate law a public corporation's board sits in three classes and its directors come off only for cause unless the company elected out, so a committee is buying a three-year term. ISS treats that failure to opt out as an adverse vote trigger.
01 — The brief answer
Why board search Boston mandates stall at the class boundary, and what closes them
Boston's public-company boards carry a lock Delaware's default does not impose: of the 307 proxy statements Massachusetts registrants filed on EDGAR in the twelve months to August 2026, 152 describe a board divided into three classes. Sartori's Boston interview cohort — 250 structured interviews with partners, general counsel and sitting directors — puts that class question ahead of the retainer in 71% of refusals we logged. Under section 8.06 of the Massachusetts Business Corporation Act a public corporation's directors sit in three staggered classes and come off only for cause unless the company elected out.
The failure is procedural, not commercial. A candidate who joins in October stands for a full three-year term at that class's next election, and the ISS benchmark policy effective 1 February 2026 treats failing to opt out of a state classified-board law as an adverse vote trigger. A Boston seat is a three-year purchase made on one meeting's evidence. Files close when the class assignment, overboarding count and conflict map are settled before the first approach; they stall when the shortlist comes first.
Sartori has worked in the Boston market for 8 years, for Nasdaq-listed life sciences issuers, academic medical centers and sponsor-backed platforms. Over the last three years Sartori closed 8 Board & Non-Executive Director Search searches at a 94% completion rate, with a median timeline of 4 to 7 months. Committees running board search Boston mandates usually call in week six, after two names have failed the ISS five-board test.
Years in this market
8years
Searches closed · 3 yrs
8
Completion rate
94%
Median timeline
4to 7 months
Sartori & Partners trailing record · Board & Non-Executive Director Search · Boston
02 — The local market
Boston's listed and regulated employer base, and the composition regime that binds its boards
Boston's board market rests on three employer blocks with no governance shape in common. MassBio counted 113,503 Massachusetts biopharma jobs in 2025, down 3.1% and roughly 3,600 jobs, the first annual fall since the state's 2008 life sciences initiative, while 107 of the 650 US annual reports to August 2026 describing the filer as clinical-stage were Massachusetts registrants. Beside them sit 24 hospital health systems and 61 acute hospitals at a median operating margin of minus 2.7%, and 83 state-chartered banks and 48 credit unions holding $594 billion under the Massachusetts Division of Banks.
Four regimes bind the same room. Nasdaq Rule 5605(c) requires 3 independent audit committee members who can read financial statements; Exchange Act Rule 10A-3 bars any of them from taking a consulting or advisory fee; Regulation S-K Item 407(d)(5) makes a registrant name an audit committee financial expert or explain the gap; and Item 106(c), effective 4 August 2023, makes it name the cybersecurity oversight committee. Section 8.06 of the Massachusetts Business Corporation Act then fixes how long the appointee stays.
The proxies show the load. Of 307 Massachusetts proxy statements filed in the year to August 2026, 262 name an audit committee financial expert and 202 discuss cybersecurity. Five in six Massachusetts proxies name a financial expert; two in three now discuss cyber. Sartori's coverage runs to roughly 3,500 Boston lawyers we map, against 60,956 attorneys on active status statewide at the end of fiscal 2025.
03 — Selected engagements
Recent board & non-executive director search work in Boston
Anonymised mandates from our Boston book — profile, complication and outcome. Select an engagement to open its file.
BOSTON × BOARD & NON-EXECUTIVE DIRECTOR SEARCH3 ENGAGEMENTS · ANONYMISED
Audit-committee financial expert for a Nasdaq-listed clinical-stage biopharmaceutical company
A Massachusetts-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company in the Boston area, roughly $900 million market capitalization, with a board of 8 divided into three classes
Mandate
One audit-committee financial expert meeting the Item 407(d)(5) attributes, assigned to the class next standing in 14 months and able to take the chair within a year
Complication
Three of the first six names failed a screen rather than an interview: two had taken advisory fees inside the Rule 10A-3 look-back, and one already sat on 5 public boards, which would have tripped the ISS ceiling on election. The company had never elected out of the state classified-board default, so the seat carried a full three-year term rather than the one-year trial the client had described to candidates
Outcome
Seated a former divisional finance chief of a commercial-stage device group as audit chair-elect, with the class assignment and a standing committee budget for outside advisers agreed before the offer went out
Technology and cyber risk seat after a first Item 106(c) disclosure
A Massachusetts medical-device manufacturer listed on a US exchange, about $2.4 billion market capitalization, with cybersecurity oversight parked on an audit committee of 3
Mandate
One non-executive director able to hold technology and cyber risk oversight and to sit on audit without breaching the Rule 10A-3 fee bar
Complication
The two candidates with the deepest operating security records had both consulted for the company inside the three-year look-back, and a third withdrew when the board would not move the appointment from the class expiring in 2 months to the class expiring in 26
Outcome
Appointed a former chief information security officer of a regulated health-data business into the longer class, with a standing technology review added to the audit committee calendar
Legal and compliance NED seated during a chief-executive transition
A sponsor-backed health services platform headquartered in Greater Boston, about $600 million of revenue, preparing to list within 24 months while replacing its chief executive
Mandate
One non-executive director with regulatory and compliance judgment to chair a new compliance committee and sit on audit
Complication
The specification moved twice in six weeks as the incoming chief executive asked for sector operating history and the sponsor asked for listing readiness, and 2 of 5 finalists took competing seats while it stayed open
Outcome
Placed a former general counsel of a regulated care group who had taken a company through a first proxy season, seated 11 weeks before the new chief executive started
04 — Mandates we run
Which Boston committee seats go unfilled: audit financial expert, cyber and technology risk, legal and compliance, ESG
Sartori's Boston mandate records show that of the 8 board and non-executive director searches we closed over three years, 3 were audit-committee financial expert seats, 2 technology and cyber risk, 2 legal and compliance, and 1 sustainability. The audit seat dominates because Item 407(d)(5) turns an absence into a disclosed gap, and Rule 10A-3 removes the adviser closest to the balance sheet.
Supply is moving against the legal seat. EY reported in August 2026 that 37% of S&P 500 companies cite AI experience for at least one director, against 11% in 2022, while the share of S&P 500 directors carrying that experience reached 5%, up from 1%. Set against the average S&P 500 board of 10.8 directors in EY's March 2025 governance data, that is roughly one and a half AI-literate names on the boards that disclose any. The one open seat is being spent on technologists. Item 106(c) then hands that same board legal and regulatory risk to supervise.
Committee design has not caught up. EY's 2025 review of Fortune 100 disclosures found 96% assign cybersecurity oversight to a board committee, but only 11% run a dedicated technology committee and 78% park it on audit. A general counsel at a Nasdaq-listed clinical-stage company told us her nominating chair sent back two shortlists because both finalists already sat on 5 public boards. The sustainability brief arrives rewritten here: supply-chain and product-safety oversight attached to audit, not a standalone committee.
Hiring in Boston?
We map this market every day.
The market intelligence on this page is the same coverage we use to run retained board & non-executive director search mandates in Boston.
What a Boston NED seat pays, and why NED recruitment here prices the committee
Boston's dominant sector is the highest-paying board sector in the country, and that is the trap in the brief. The Conference Board's February 2026 analysis of Russell 3000 and S&P 500 practice puts health care board medians above $320,000, against just over $180,000 at financial firms and $257,000 across the Russell 3000 as a whole. Most Boston issuers are Russell 3000 companies wearing a health care label, so the sector median overstates the local seat by roughly a quarter before a single negotiation starts.
The structure holds even where the level does not. Russell 3000 cash retainers held at $75,000 against $105,000 in the S&P 500, stock awards at $150,000 against $190,000, and total committee chair premiums at $61,000 against $116,250. Growth has flattened to 11% over three years in the Russell 3000, down from 31% since 2019, and 52% of Russell 3000 companies now cap total director pay, up from 33% in 2021, typically at $750,000.
Sartori's Boston mandate telemetry records a median offer-to-acceptance of 24 working days across board and NED offers, and a counter-offer incidence of 14%, which here means a competing seat rather than a pay match. A compensation committee chair at a mid-cap Massachusetts industrial described the audit-chair premium to us as three extra weekends a quarter rather than a fee. In Boston the retainer settles fast; the class assignment does not.
06 — Live market
Board composition and refreshment in Boston: how a class seat actually opens
EY's governance database, current to 31 March 2025 and covering 1,700-plus US public companies, records annual director elections at 88% of the S&P 500 but at only 69% of the S&P MidCap 400 and 66% of the S&P SmallCap 600.
The staggered board is a small-cap structure. That 22-point gap lands on Boston, whose clinical-stage issuers sit in that band. EY puts average director tenure at 9 years in every index it tracks; Glass Lewis's 2026 policy flags the nominating chair where non-executive directors average 10 years or more with no new independent director in five years. A mid-class Massachusetts resignation is filled by the remaining directors for the balance of that term, so the appointee faces no shareholder vote until the class expires.
New boards supply the seats: Massachusetts life sciences companies completed 8 IPOs in the first half of 2026, all on Nasdaq, as many as 2024 and 2025 together and 8 of the 13 US biotech listings. Chief-executive transitions move them too: Glass Lewis's 2026 policy recommends against a sitting public-company executive officer holding more than one external board seat. Sartori's Boston survey wave for 2026 finds 5 of our 8 closed board files opened on an event: a listing, a mid-class resignation or a chief-executive transition. Our Boston telemetry cannot see privately held, family-controlled and nonprofit hospital boards, which never publish a seat.
07 — Methodology
How we run a Boston board advisory search
01 — BriefMandate, success profile and conflicts frame agreed in writing.
02 — Market mapThe live universe mapped from our coverage, not whoever is in motion.
03 — ApproachConfidential, principal-led conversations with the mapped shortlist.
04 — ShortlistUnderwritten candidates presented with evidence, not CVs.
05 — OfferPackage design, references and counter-offer defence.
06 — CloseResignation, notice and the first hundred days, managed.
Median 4 to 7 months from signed brief to accepted offer on closed Boston mandates.
A Boston mandate starts in the articles of organization, not in the shortlist. We check whether the company elected out under section 8.06(c) of the Massachusetts Business Corporation Act, which class the vacancy sits in and when that class next stands, then read three years of Form 8-K director-change filings, the committee charters and the proxy independence disclosures. Where the client is a hospital system or an endowment, the equivalent documents are the bylaws and the conflict-of-interest policy.
Every name is screened before it becomes a name. Candidates are tested against the ISS ceiling of 5 public company boards, against the Rule 10A-3 bar on consulting and advisory fees for audit members, and against the Item 407(d)(5) financial-expert attributes. Of the 88 nominating and governance committee members inside our Boston cohort, 61% required a written class assignment before agreeing to a second meeting, across an 18-month window.
The private material behind that is Sartori's own: roughly 1.5 million lawyer profiles mapped globally, quarterly market surveys running since 2019, and 250 structured interviews with Boston partners, counsel and sitting directors. Boston coverage runs to about 3,500 lawyers we map. Across 31 board and committee approaches logged on our 8 closed Boston files over 24 months, 39% of first-choice candidates declined before a formal offer, most citing the class term. A Boston board advisory search runs 4 to 7 months at our median, with 24 working days between offer and acceptance.
Hiring in Boston?
Brief us on the search.
Whether you are building a team or weighing a move, we listen first. No obligation.
1Sartori & Partners — Boston Legal Talent Research Programme (250 structured interviews; ~3,500 lawyers mapped; quarterly surveys since 2019; mandate telemetry)Boston interview-cohort findings on why directors refuse a seat (250 structured interviews with partners, general counsel and sitting directors over 24 months: 71% put the three-year class term ahead of the retainer; 88 nominating and governance committee members, 61% of whom required a written class assignment before a second meeting across an 18-month window); mandate records on 8 closed Boston board searches (3 audit financial expert, 2 technology and cyber risk, 2 legal and compliance, 1 sustainability; 5 opened on an event; 2 stalled past a class boundary); telemetry on a 24-working-day median offer-to-acceptance and 14% counter-offer incidence; 31 board and committee approaches over 24 months with a 39% pre-offer decline rate; Boston mapping coverage of ~3,500 lawyers and the quarterly survey wave running since 2019
4SEC EDGAR full-text search — Massachusetts-located registrants, filings dated 1 September 2025 to 26 August 2026Massachusetts filing counts underpinning the local market read: 307 DEF 14A proxy statements, of which 262 name an audit committee financial expert, 202 discuss cybersecurity and 152 describe three classes of directors; 559 Form 8-K reports of director departures and elections; 107 of the 650 US annual reports describing the filer as clinical-stage
5MassBio — 2026 Industry Snapshot (Massachusetts life sciences, full-year 2025 data)The Massachusetts biopharma employer base: 113,503 biopharma jobs in 2025, down 3.1% and roughly 3,600 jobs, the first annual decline since the 2008 state life sciences initiative; 8 Massachusetts life sciences IPOs in the first half of 2026, all on Nasdaq, equal to 2024 and 2025 combined and 8 of the 13 US biotech listings in the half
Board & Non-Executive Director Search in Boston — common questions
Who are the best board & non-executive director search in Boston?
Boston has no verified ranking of board & non-executive director search. What can be checked is coverage of the market, stated method and the record on closed searches. Sartori & Partners maps roughly 3,500 lawyers in Boston and has worked this market for 8 years. Over the trailing three years we closed 8 board & non-executive director search searches here at a 94% completion rate, with a median timeline of 4 to 7 months. Across 250 structured interviews with Boston partners, general counsel and sitting directors over 24 months, 71% put the three-year class term ahead of the retainer as the reason for refusing a Boston seat. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
How long does a board search Boston mandate take, brief to seated director?
Four to seven months is our Boston median, with 24 working days of that between offer and acceptance. Committee calendars set the pace: a board that meets quarterly adds four to six weeks to any timeline that misses a meeting, and a class boundary can add a full quarter. Our 8 closed Boston board searches over three years ran a 94% completion rate.
Why does a Massachusetts board seat run three years instead of one?
Because section 8.06 of the Massachusetts Business Corporation Act divides a public corporation's board into three classes unless the company elected out under paragraph (c). Directors under that structure are removable by shareholders only for cause, and vacancies are filled by the remaining directors for the balance of the class term. Of 307 Massachusetts proxy statements filed in the twelve months to August 2026, 152 describe a three-class board.
Which Boston committee seat is hardest to fill?
The audit-committee financial expert seat at a clinical-stage issuer: 3 of the 8 Boston board searches we closed over three years were that seat. Item 407(d)(5) forces the disclosure, Nasdaq Rule 5605(c) requires 3 independent members who can read financial statements, and Rule 10A-3 bars anyone taking a consulting or advisory fee from the issuer. In a market where 107 clinical-stage filers compete for the same finance directors, the fee bar removes the obvious names first.
What does a Boston non-executive director seat pay?
Health care boards paid a median above $320,000 in The Conference Board's February 2026 analysis, against $257,000 across the Russell 3000. Most Boston issuers are Russell 3000 companies with a health care label, so the sector headline overstates the local seat by roughly a quarter. Russell 3000 cash retainers held at $75,000 with stock awards at $150,000, and 52% of those companies now cap total director pay, typically at $750,000.
How many public boards can a Boston candidate already sit on?
ISS recommends voting against any director who sits on more than 5 public company boards, or any public-company CEO on more than 2 outside boards. That ceiling bites hard in a market where serial life sciences directors accumulate seats quickly. We run the count before the first approach: two names had already failed it on the average file that reached us in week six.
What separates a Boston board file that closes from one that stalls?
Settling the class assignment, the overboarding count and the conflict map before the first approach: 2 of our 8 closed Boston files stalled when we did not. Both restarted with a rewritten specification and added roughly three months each. The pattern is consistent across our records: a file that reaches candidates before the class question is answered loses its first-choice name to the delay.
We use analytics to understand how the site is used, including heatmaps and session
replay. No advertising cookies. See our
Cookie Policy and Privacy Policy.
